Mumbai, Feb. 12 -- Revenue from operations jumped 44% to Rs 440.29 crore in Q3 FY25 as compared with Rs 305.79 crore in Q3 FY24.

Profit before tax (PBT) soared 106% to Rs 42.02 crore in Q3 FY25 as compared with Rs 20.40 crore in Q3 FY24.

In Q3 FY25, revenue from Oncology stood at Rs 293.90 crore, while Biopharmaceuticals (CVRM, R&I, and V&I) generated Rs 120.97 crore. Revenue from rare diseases amounted to Rs 0.6 crore during the period under review.

Meanwhile, the company received a warning letter from BSE. The letter stated that it was observed that the company is in non-compliance with the provisions of Regulation 18{2)(b) of SEBI (LODR) Regulations, 2015 as only one independent director attended the audit committee meeting held on ...